Cardiovascular safety and diabetes drug development

被引：34
作者：
Drucker, Daniel J. [1 ]
Goldfine, Allison B. [2 ]
机构：
[1] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada
[2] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA
来源：
LANCET | 2011年 / 377卷 / 9770期
关键词：
EXENATIDE TWICE; OPEN-LABEL; TYPE-2; LIRAGLUTIDE; THERAPIES; OUTCOMES; WEIGHT; RISK;
D O I：
10.1016/S0140-6736(10)62299-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：977 / 979
页数：3
相关论文
共 14 条
[1]   Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies [J].
Ban, Kiwon ;
Hui, Sonya ;
Drucker, Daniel J. ;
Husain, Mansoor .
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2009, 3 (04) :245-259
[2]   Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily [J].
Best, J. H. ;
Boye, K. S. ;
Rubin, R. R. ;
Cao, D. ;
Kim, T. H. ;
Peyrot, M. .
DIABETIC MEDICINE, 2009, 26 (07) :722-728
[3]   Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database [J].
Best, Jennie H. ;
Hoogwerf, Byron J. ;
Herman, William H. ;
Pelletier, Elise M. ;
Smith, Daniel B. ;
Wenten, Made ;
Hussein, Mohamed A. .
DIABETES CARE, 2011, 34 (01) :90-95
[4]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[5]   Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes [J].
Chatterjee, Dhruba J. ;
Khutoryansky, Naum ;
Zdravkovic, Milan ;
Sprenger, Craig R. ;
Litwin, Jeffrey S. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (11) :1353-1362
[6]   Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].
Drucker, Daniel J. ;
Buse, John B. ;
Taylor, Kristin ;
Kendall, David M. ;
Trautmann, Michael ;
Zhuang, Dangliang ;
Porter, Lisa .
LANCET, 2008, 372 (9645) :1240-1250
[7]   A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes [J].
Frederich, Robert ;
Alexander, John H. ;
Fiedorek, Fred T. ;
Donovan, Mark ;
Berglind, Niklas ;
Harris, Susan ;
Chen, Roland ;
Wolf, Robert ;
Mahaffey, Kenneth W. .
POSTGRADUATE MEDICINE, 2010, 122 (03) :16-27
[8]   Assessing the cardiovascular safety of diabetes therapies [J].
Goldfine, Allison B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (11) :1092-1095
[9]   Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects [J].
James, W. Philip T. ;
Caterson, Ian D. ;
Coutinho, Walmir ;
Finer, Nick ;
Van Gaal, Luc F. ;
Maggioni, Aldo P. ;
Torp-Pedersen, Christian ;
Sharma, Arya M. ;
Shepherd, Gillian M. ;
Rode, Richard A. ;
Renz, Cheryl L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) :905-917
[10]   Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes [J].
Kim, Dennis ;
MacConell, Leigh ;
Zhuang, Dongliang ;
Kothare, Prajakti A. ;
Trautmann, Michael ;
Fineman, Mark ;
Taylor, Kristin .
DIABETES CARE, 2007, 30 (06) :1487-1493
12